Skip to main content
. Author manuscript; available in PMC: 2024 Mar 15.
Published in final edited form as: Alzheimers Dement. 2024 Jan 24;20(3):2298–2308. doi: 10.1002/alz.13674

FIGURE 3.

FIGURE 3

Growth of grant funding and articles in the top 10 areas of LBD research. Lysosomal Glucocerebrosidase activity/functions excluded from plot due to too low n to calculate CAGR; Caregiving/cognition rehab excluded due to out of scope of workshop focus. Growth measured by CAGR. CAGR values for ‘3′ calculated using 2017–2021 data. Projects under “Alpha-synuclein Targeting Therapeutic Approaches” categorized as “Drug discovery/drug target identification.” Source: BCG analysis and Lee et al.7. BCG, Boston Consulting Group; CAGR, compound annual growth rate; LBD, Lewy body dementia